Oppenheimer Holdings, Inc. Reiterates Buy Rating for BioLineRx Ltd. (BLRX)

BioLineRx Ltd. (NASDAQ:BLRX)‘s stock had its “buy” rating reaffirmed by Oppenheimer Holdings, Inc. in a research note issued on Tuesday. They currently have a $3.00 target price on the biotechnology company’s stock. Oppenheimer Holdings, Inc.’s price target suggests a potential upside of 188.46% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on the company. Zacks Investment Research cut BioLineRx from a “buy” rating to a “sell” rating in a report on Tuesday, June 20th. Maxim Group upgraded BioLineRx from a “hold” rating to a “buy” rating and upped their price target for the stock from $1.00 to $3.00 in a report on Thursday, May 18th. ValuEngine upgraded BioLineRx from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Roth Capital started coverage on BioLineRx in a report on Thursday, August 3rd. They set a “buy” rating and a $3.00 target price on the stock. Finally, HC Wainwright set a $4.00 target price on BioLineRx and gave the company a “buy” rating in a report on Saturday, May 27th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. BioLineRx has an average rating of “Buy” and an average price target of $2.59.

BioLineRx (BLRX) traded down 0.481% during trading on Tuesday, hitting $1.035. The stock had a trading volume of 236,079 shares. The firm’s market cap is $98.96 million. BioLineRx has a 12-month low of $0.80 and a 12-month high of $1.42. The stock’s 50 day moving average price is $1.07 and its 200 day moving average price is $0.97.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). On average, analysts anticipate that BioLineRx will post ($0.24) EPS for the current fiscal year.

WARNING: This piece was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.themarketsdaily.com/2017/09/12/oppenheimer-holdings-inc-reiterates-buy-rating-for-biolinerx-ltd-blrx.html.

Several institutional investors have recently modified their holdings of the business. Sabby Management LLC purchased a new position in shares of BioLineRx during the 1st quarter worth $3,018,000. KCG Holdings Inc. lifted its stake in shares of BioLineRx by 715.9% during the 1st quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 153,687 shares during the period. Benchmark Capital Advisors lifted its stake in shares of BioLineRx by 227.3% during the 1st quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 100,000 shares during the period. Renaissance Technologies LLC purchased a new position in shares of BioLineRx during the 1st quarter worth $126,000. Finally, Citadel Advisors LLC lifted its stake in shares of BioLineRx by 443.4% during the 1st quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 86,481 shares during the period. 32.27% of the stock is currently owned by institutional investors.

BioLineRx Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply